|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM326660720 |
| 003 |
DE-627 |
| 005 |
20240726231947.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202100628
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1482.xml
|
| 035 |
|
|
|a (DE-627)NLM326660720
|
| 035 |
|
|
|a (NLM)34118167
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ngamcherdtrakul, Worapol
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.07.2024
|
| 500 |
|
|
|a Date Revised 26.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 Wiley-VCH GmbH.
|
| 520 |
|
|
|a The success of immunotherapy with immune checkpoint inhibitors (ICIs) in a subset of individuals has been very exciting. However, in many cancers, responses to current ICIs are modest and are seen only in a small subsets of patients. Herein, a widely applicable approach that increases the benefit of ICIs is reported. Intratumoral administration of augmenting immune response and inhibiting suppressive environment of tumors-AIRISE-02 nanotherapeutic that co-delivers CpG and STAT3 siRNA-results in not only regression of the injected tumor, but also tumors at distant sites in multiple tumor model systems. In particular, three doses of AIRISE-02 in combination with systemic ICIs completely cure both treated and untreated aggressive melanoma tumors in 63% of mice, while ICIs alone do not cure any mice. A long-term memory immune effect is also reported. AIRISE-02 is effective in breast and colon tumor models as well. Lastly, AIRISE-02 is well tolerated in mice and nonhuman primates. This approach combines multiple therapeutic agents into a single nanoconstruct to create whole-body immune responses across multiple cancer types. Being a local therapeutic, AIRISE-02 circumvents regulatory challenges of systemic nanoparticle delivery, facilitating rapid translation to the clinic. AIRISE-02 is under investigational new drug (IND)-enabling studies, and clinical trials will soon follow
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a intratumoral therapy
|
| 650 |
|
4 |
|a melanoma
|
| 650 |
|
4 |
|a nanotechnology
|
| 650 |
|
4 |
|a translational research
|
| 650 |
|
7 |
|a STAT3 Transcription Factor
|2 NLM
|
| 650 |
|
7 |
|a RNA, Small Interfering
|2 NLM
|
| 650 |
|
7 |
|a Cancer Vaccines
|2 NLM
|
| 700 |
1 |
|
|a Reda, Moataz
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nelson, Molly A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Ruijie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zaidan, Husam Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bejan, Daniel S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hoang, Ngoc Ha
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lane, Ryan S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luoh, Shiuh-Wen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Leachman, Sancy A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mills, Gordon B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gray, Joe W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lund, Amanda W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yantasee, Wassana
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 33(2021), 31 vom: 15. Aug., Seite e2100628
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:2021
|g number:31
|g day:15
|g month:08
|g pages:e2100628
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202100628
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2021
|e 31
|b 15
|c 08
|h e2100628
|